Source link : https://www.newshealth.biz/health-news/ivonescimab-tops-pembro-in-advanced-pd-l1-positive-nsclc/
First-line treatment with ivonescimab led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) in patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to recent findings from the HARMONi-2 trial. “This is the first randomized, phase 3 study to demonstrate a clinically significant improvement in efficacy […]
Author : News Health
Publish date : 2024-09-08 20:53:15
Copyright for syndicated content belongs to the linked Source.